Tools and Techniques for Wt1-Based Lineage Tracing. by Wilm, Bettina & Muñoz-Chapuli, Ramon
1 
 
Tools and techniques for Wt1-based lineage tracing   
 
Bettina Wilm
1,*
 and Ramon Muñoz-Chapuli
2,*
 
1 Department of Cellular and Molecular Physiology, Institute of Translational 
Medicine, University of Liverpool, Liverpool, UK, b.wilm@liv.ac.uk 
2  Department of Animal Biology, Faculty of Science, University of Malaga, Malaga, 
Spain, chapuli@uma.es 
*  both authors are corresponding authors. 
 
Running Head: Tools and techniques for Wt1-based lineage tracing   
  
2 
 
 
i. Summary / Abstract 
The spatiotemporal expression pattern of Wt1 has been extensively studied in a 
number of animal models to establish its function and the developmental fate of the 
cells expressing this gene. In this chapter, we review the available animal models for 
Wt1-expressing cell lineage analysis, including direct Wt1 expression reporters and 
systems for permanent Wt1 lineage tracing. We describe the presently used 
constitutive or inducible genetic lineage tracing approaches based on the Cre/loxP 
system utilising Cre recombinase expression under control of a Wt1 promoter.  
To make these systems accessible, we provide laboratory protocols that include 
dissection and processing of the tissues for immunofluoresence and histopathological 
analysis of the lineage-labelled Wt1-derived cells within the embryo/tissue context. 
 
ii. Key words 
Wt1, cell lineage tracing, Cre/loxP, inducible Cre recombinase, Cre-ERT2, 
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1. Introduction 
A number of murine models are available to study both, Wt1-expressing cell lineage 
and actual Wt1 expression. The first models are based on a Cre/loxP system, inducing 
constitutive expression of a reporter gene in those cells where the Wt1 promoter 
controls expression of the Cre-recombinase enzyme. Different levels of 
recombination can produce different levels of reporter expression, and rigorous 
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controls using Cre-/-; Flox+/+ embryos must be performed to discard events of 
spontaneous recombination. On the other hand, direct activation of a reporter gene by 
the Wt1 promoter allows to directly monitor Wt1 expression in the tissues. The 
replacement of the exon 1 of the Wt1 gene by a GFP expressing system (Wt1 knock-
in system, 1) also allows for detection of Wt1 expression in heterozygous (Wt1
+/GFP
) 
embryos using the original Wt1 promoter (see below).  
 
Direct Wt1 expression reporters: 
Wt1-expressing cells in tissues can be analysed using in situ hybridisation and 
immunohistochemical approaches. However, a set of mouse lines that function as 
direct Wt1-LacZ or-GFP reporters, enable detection of cells that are expressing Wt1 
at any given time (2-5). The Wt1-LacZ reporters were generated initially by yeast 
recombineering of YAC clones containing the human WT1 locus with a LacZ-
containing cassette, before pronuclear injections of the resulting YAC constructs gave 
rise to a range of transgenic LacZ reporters (Tg(WT1)HNdh, Tg(WT1)WANdh, 
Tg(WT1)WCNdh, Tg(WT1)WWNdh; Refs. 2, 3). Analysis of these transgenic Wt1-
LacZ reporter lines revealed a highly faithful recapitulation of endogenous Wt1 
expression in a range of embryonic tissues, and some degree of rescue function by 
combination with Wt1
-/-
 mutants.  
By contrast, the Wt1
tm1Nhsn
 reporter mouse line was generated as knock-in of a GFP-
cassette containing construct by gene targeting, thus replacing exon1 and part of the 
intronic region in the resulting mouse line Wt1
tm1Nhsn
 (5). In Wt1
tm1Nhsn
 heterozygous 
mice, GFP is expressed directly under control of the endogenous Wt1 promoter 
elements, while Wt1
tm1Nhsn
 homozygous mice are embryonic lethal due to the 
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inactivation of the Wt1 locus at the GFP insertion site. The GFP expression can be 
observed directly under the dissecting microscope (Figure 1A) or by confocal 
microscopy, but the signal can also be much enhanced by GFP immunolocalization 
(Figure 1B). 
The GFP reporter line Wt1
tm1(EGFP/cre)Wtp
 was generated following a similar gene 
targeting strategy, and also results in GFP expression under direct control of the 
endogenous Wt1 promoter. However, in this mouse line, GFP is fused with the Cre 
recombinase protein, providing these mice with dual function for direct labelling of 
Wt1 expression, and as tool for lineage tracing studies (6). Both mouse lines have 
been proven useful as tools to study Wt1 expression in embryonic tissues, but also in 
isolated cells in vitro. Two further transgenic mouse lines which carry eGFP in 
combination with Cre recombinase under control of a Wt1 promoter have been 
described (Tg(Wt1-cre)#Jbeb, Ref. 7; Tg(Wt1-EGFP/cre)1Akis, Ref. 8), but their use 
as direct reporters for Wt1-controlled GFP expression have not been demonstrated. 
As shown below, GFP expression in Tg(Wt1-cre)#Jbeb animals is below the detection 
limit. 
 
Permanent Wt1 lineage tracing – constitutive Cre recombinase expressed under 
control of Wt1: 
Six different mouse lines have been described that utilise constitutive Cre 
recombinase expression under control of the mouse or the human WT1 gene for 
permanent lineage tracing (Figure 2): 
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 Wt1-Cre, first described by the Bader lab (9) (official nomenclature 1 : 
Tg(WT1-cre)AG11Dbdr; MGI:3609978) 
 mWt1/IRES/GFP-Cre or Wt1Cre, generated by the Burch lab (7) (official 
nomenclature: Tg(Wt1-cre)#Jbeb; MGI:5308608) 
 Wt1GFPCre, generated by the Pu lab (6) (official nomenclature: 
Wt1
tm1(EGFP/cre)Wtp
; MGI:3801681) 
 Wt1BAC-IRES-EGFPCre, generated by the Kispert lab (8) (official nomenclature: 
Tg(Wt1-EGFP/cre)1Akis; MGI:5002800) 
 WT1(RP23-8C14)-Cre, generated by the Burch lab (10) (official 
nomenclature: Tg(Wt1-cre)1Jbeb; MGI:5562908) 
Similar protocols for permanent lineage tracing of Wt1-expressing cells have been 
described for all mouse lines of this category. Here, we detail the lineage tracing 
protocol using the mWt1/IRES/GFP-Cre (Wt1
Cre
) mouse line. 
The Wt1
Cre 
mouse line was developed using a BAC recombineering strategy to insert 
an IRES/EGFP-CRE cassette 17 bp downstream of the translation stop site of the 
Wt1 gene in the BAC clone RP23-266M16. The resultant recombinant BAC clone 
was used to generate several independent transgenic mouse lines that express Cre in 
the epicardial lineage beginning at the proepicardial stage. These Wt1
Cre
 transgenic 
mice have been used in previous studies to trace or delete specific genes in Wt1-
expressing cells (7, 11, 12, 13). Crossing of homozygote (Wt1
Cre+/+
) mice with 
B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J mice (Rosa26R-EYFP in short) allows 
to generate permanent reporter expression in Wt1-expressing cells (Figure 3A,B).  
                                                             
1Official nomenclature of mouse lines can be found under the Jackson laboratory website: 
www.informatics.jax.org 
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Of note, the Cre driver used for these studies induces the expression of low levels of 
GFP, but this expression does not interfere with the YFP expression of the reporter. 
Control Wt1
Cre+/+
; Rosa26R-EYFP
−/−
 embryos show no detectable GFP levels in the 
embryonic tissues by confocal microscopy (Figure 3C,D).  
Temporal control of Wt1 lineage tracing - inducible Cre recombinase expressed 
under control of Wt1: 
So far, one mouse line has been described that allows temporal induction of Cre 
recombinase activity under control of Wt1 transcriptional regulation: 
 Wt1CreERT2, generated in the Pu lab (6) (official nomenclature: 
Wt1
tm2(cre/ERT2)Wtp
; MGI:3801682). 
The Wt1
CreERT2
mouse line was generated by gene targeting a construct containing the 
Cre-ERT2 recombinant expression cassette in alignment with the start codon, thus 
replacing the first coding exon. In the Wt1
CreERT2
 mouse line, Cre recombinase 
activity is induced by administration of Tamoxifen to mice. The Cre recombinase in 
these mice is fused to a modified estrogen receptor (ERT2; Ref. 14). The Cre-ERT2 
fusion protein can only enter the nucleus when binding of Tamoxifen to the ERT2 
part of the fusion protein has led to a conformational change; in the absence of 
Tamoxifen, the Cre-ERT2 fusion protein is localised in the cytoplasm. In mice 
carrying the Wt1
CreERT2
 allele and a genomic region flanked by loxP recognition sites, 
the Cre recombinase can remove the loxP-flanked elements after Tamoxifen 
administration. 
Because Tamoxifen is required for the activation of Cre recombinase activity, it 
allows for temporal control of reporter gene activity. Thus, the system enables the 
analysis of the contribution and fate of Wt1-expressing cells at specific, defined time 
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points, either in embryonic development, or in post-natal stages. Tamoxifen as the 
inducer of Cre recombination acts as a pulse, which results in irreversible activation 
of the reporter expression only when Tamoxifen has led to the Cre-ERT2 
conformational change. The time that passes between Tamoxifen-induced 
recombination (‘pulse’) and time point of analysis represents the ‘chase’ (Figure 4): 
cells that change their fate and/or position within the tissue through differentiation 
and/or migration, may downregulate Wt1 and Cre expression, but will still be 
detectable for the reporter expression. Assessment of change in fate over time can be 
performed using immunohistochemistry with differentiation-specific markers. 
Wt1
CreERT2
 mice have been successfully used for lineage tracing studies in 
combination with Rosa26R-LacZ (15, 16), Rosa26R-EYFP (17) or Rosa26R-mTmG 
mice (4, 6, 17, 18, Wilm et al., in preparation; Figure 5). For more information on 
Cre-specific reporter mouse strains, we refer to the Jackson laboratory website 
(http://cre.jax.org/crereporters.html). 
Most applications using the Wt1
CreERT2
;reporter system involve embryonic lineage 
tracing studies where Tamoxifen is administered once at a specific time point during 
development (4, 6, 19-22). However, in studies where adult Wt1-expressing cells are 
traced, either in unchallenged or injured animals, Tamoxifen is usually administered 
on several occasions within 1-2 weeks, followed by a wash-out period (23, 24, Wilm 
et al., in preparation).  
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2. Materials  
Solutions for histological analysis are prepared from analytical grade chemicals with 
autoclaved destilled water. Solutions are autoclaved, where appropriate, and stored at 
room temperature, 4 °C or -20 °C. 
2.1 Tamoxifen solution and administration 
1. 40 mg/ml Tamoxifen solution: weigh 1 g Tamoxifen (for example: T5648, Sigma) 
into a 50 ml universal tube and add 2.5 ml of 100% Ethanol (molecular grade). Mix 
thoroughly and then add 22.5 ml corn oil (for example: C8267, Sigma). Transfer 
solution to small bottle wrapped in foil, add a small stir bar and store at 4 °C. (see 
Note 1).  
2.  Oral gavage needle (available in a range of sizes from different companies) 
 
2.2 Preparation of tissue for frozen sections 
1. 10x PBS stock solution: weigh in 80 g NaCl2, 2 g KCl, 14.4 g Na2HPO4 and 2.4 g 
KH2HPO4 in a 2 l beaker, and add 800 ml destilled H2O. Dissolve using a stir bar on a 
magnetic stirrer, and adjust pH to 7.4 using concentrated HCl. Once pH is adjusted, 
transfer solution to 1000 ml graduated cylinder and add distilled H2O to make 1000 
ml. Fill into a clean blue-capped bottle, autoclave and store at room temperature. 
2. Phosphate Buffered Saline (PBS): either dilute 10x PBS stock solution to 1x 
working solution, or make up from PBS tablets (for example: P4417, Sigma), using 
destilled, autoclaved H2O. 
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3. 4% Paraformaldehyde (PFA) solution: weigh in 10 g PFA and dissolve in 200 ml 
destilled H2O and 25 ml 10x PBS, under constant stirring and by slowly warming up 
the solution to maximum of 60°C, in the fume cupboard. Avoid breathing in the toxic 
fumes! Once solution has cleared, make solution up to 250 ml using destilled H2O in 
a measuring cylinder. Transfer 4% PFA solution into a clean bottle, autoclave and 
store at 4 °C, or aliquot and store at -20 °C. 
4. 15% sucrose in PBS: weigh in 15 g Sucrose and dissolve in 80 ml PBS; rotating 
and warming helps the sucrose to dissolve. Once dissolved, make solution up to 100 
ml using PBS in a measuring cylinder, aliquot in 15 ml universal tube and store at -20 
°C (see Note 3). 
5. 30% sucrose in PBS: weigh in 30 g Sucrose and dissolve in 60 ml PBS; rotating 
and warming helps the sucrose to dissolve. Once dissolved, make solution up to 100 
ml using PBS in a measuring cylinder, aliquot in 15 ml universal tube and store at -20 
°C (see Note 3). 
6. Optimal cutting temperature compound (OCT; Tissue Tek or other suppliers) 
7. Cryostat including anti-roll blade, cryoblades  
8. Superfrost Plus glass slides (Thermo Scientific or other suppliers) 
9. Isopentane 
 
2.3 Immunofluorescence analysis 
1. Tris-PBS (TPBS): 1x TPBS solution: Weigh 7 g NaCl2, 1.48 g Na2HPO4 and 043 g 
KH2PO4 and 5 g of Trizma base (Sigma, T1503) in a 2 l beaker, and add 800 ml 
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destilled H2O. Dissolve using a stir bar on a magnetic stirrer, and adjust pH to 7.8 
using concentrated HCl. Once pH is adjusted, transfer solution to 1000 ml graduated 
cylinder and add distilled H2O to make 1000 ml.   
2. Serum blocking solution (SB): 16% sheep serum, 1% bovine albumin in TPBS  
3. Serum blocking solution with Triton (SBT): 16% sheep serum, 1% bovine albumin, 
0.1% Triton X-100 in TPBS 
4. Avidin-Biotin blocking kit (Vector) 
5. Monovalent donkey anti-mouse IgG, Fab fragment (Jackson) 
6. Primary antibodies: available from a plethora of companies 
7. Secondary antibodies: take note to match the fluorophore with the filter sets 
available if using an epifluorescent or confocal microscope 
8. 5 mg/ml DAPI stock solution: dissolve 5 mg DAPI (for example: D9542, Sigma) in 
1 ml molecular grade H2O. Complete dissolution can take some time. Store at -20 °C.  
9. 1 g/ml DAPI working solution: dilute 1 l DAPI stock solution in 5 ml PBS. This 
solution can be directly added to the sections. 
10. Mounting medium: a 1:1 glycerol:PBS solution can be used for temporal 
mounting. Alternatively, commercial mounting media are available (eg. Gel Mount 
from Biomeda or Sigma).  
11. Humid chamber: A closed box containing a horizontal surface covered by filter 
paper moistened in distilled water. 
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2.4 X-gal staining on frozen sections 
1. 40 mg/ml X-gal stock solution: Dilute 20 mg of X-gal (for example: Boehringer 
Mannheim, #745-740) in 0.5 ml of Dimethylformamide (for example: 227056, 
Sigma).  Mix well and store at –20°C in a 1 ml tube protected from light. 
2. 100 mM KFerro II solution: Weigh in 2.11 g Potassium hexacyanoferrate(II) 
trihydrate (for example: P3289, Sigma) into a 50 ml universal container and dissolve 
in 50 ml destilled, autoclaved H2O. Wrap in foil to protect from light and store at 
room temperature. 
3. 100 mM KFerro III solution: Weigh in 1.65 g Potassium hexacyanoferrate(III) (for 
example: 244023, Sigma) into a 50 ml universal container and dissolve in 50 ml 
destilled, autoclaved H2O. Wrap in foil to protect from light and store at room 
temperature. 
4. 1 M MgCl2 solution: Weigh in 203.3 g MgCl2 hexahydrate into a 1.5 l glass 
beaker and dissolve in 800 ml destilled H2O under stirring. Using a 1000 ml 
measuring cylinder, fill solution up to 1000 ml with destilled H2O, fill into blue-
capped bottle and autoclave. Store at room temperature. 
5. X-gal dilution buffer for frozen sections: In a 50 ml universal container, add 500 
l 100 mM KFerro II solution, 500 l 100 mM KFerro III solution, 1 ml 10x PBS 
and 20 l 1 M MgCl2 to 7730 l destilled H2O and mix well.  
6. X-gal Working Solution: Warm X-gal dilution buffer to 37°C and then add 250 l 
40 mg/ml X-gal stock solution. Use immediately and discard any leftover solution. 
7. Neutral Red Solution. Weigh 3.3 g neutral red and dissolve in 1000 ml destilled 
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H2O under stirring. Commercial solutions are available (For example: N2889, 
Sigma).  
8. Eukitt mounting medium (available from different suppliers).  
 
2.5 X-gal staining of tissues 
1. 0.2% Glutaraldehyde/2% PFA fixative for whole mount X-gal staining: In a 50 ml 
universal container, mix 400 l 25% Glutaraldehyde (grade II, for example G6257 
from Sigma) and 25 ml 4% PFA solution with 24.6 ml PBS. Make fresh before each 
use (see Note 4). 
2. 20 mg/ml X-gal stock solution: Dilute 20 mg of X-gal (for example: Boehringer 
Mannheim, #745-740) in 1 ml of Dimethylformamide (for example: 227056, 
Sigma).  Mix well and store in a 1 ml tube protected from light at –20°C. 
3. 10% Nonidet P-40 solution: Dilute 1 ml Nonidet P-40 (IGEPAL CA-630, I3021, 
Sigma) in 9 ml of destilled, autoclaved H2O in a 15 ml universal container, warm up 
slightly to aid the detergent to dissolve, and store at room temperature (see Note 5).  
4. 1% Sodium deoxycholate (NaDOC) solution: Weigh in 500 mg of NaDOC (for 
example: D6750, Sigma) into a 50 ml universal container and dissolve in 50 ml of 
destilled, autoclaved H2O. Store at room temperature. 
5. Wash solution: Add 100 l 10% Nonidet P-40 to 50 ml PBS to give a final 
concentration of 0.02% Nonidet P-40 in PBS. 
6. X-gal staining solution: Mix together in a 50 ml universal container 2.5 ml 100 
mM KFerro II solution, 2.5 ml 100 mM KFerro III solution, 5 ml 10x PBS, 100 l 1 
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M MgCl2, 100 l 10% Nonidet P-40 solution and 500 l 1% NaDOC solution with 
36.8 ml destilled H2O and mix well. Add 2.5 ml 20mg/ml X-gal solution and use 
immediately; discard any leftover solution. 
 
2.6 Eosin-counterstained paraffin sections of X-gal stained tissue  
1. Isopropanol / Isopropyl alcohol (for example: W292907, Sigma) 
2. Paraffin pellets (various suppliers) 
3. Isopropanol:Paraffin solution: In a prewarmed 100 ml glass bottle, mix 50 ml 
Isopropanol with 50 ml liquid paraffin, stir and keep in a histology oven at around 
58–60 °C until further use. 
4. Histology oven, embedding station, microtome, microtome blades, histology water 
bath, stirrer 
5. Embedding cassettes (various suppliers) or Peel-A-Ways embedding molds (for 
example: 18986 or 18646A, Polysciences) 
5. Xylene, histology grade (for example: 534056, Sigma) or Histoclear (for example: 
HS-200, National Diagnostics) 
6. Superfrost Plus glass slides (Thermo Scientific or other suppliers) 
7. Glass slide racks with metal handle and staining dish (for example: 70312-20, 
EMS) 
8. 1% Eosin Y stock solution:  Weigh in 10 g Eosin Y (for example: E4009, Sigma), 
place in a 250 ml bottle, and dissolve in 200 ml destilled, autoclaved H2O. Add 800 
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ml 95-100% Ethanol to generate a 1% Eosin Y stock solution. Store at room 
temperature. 
9. 0.25% Eosin Y staining solution: Dilute the Eosin Y stock solution further by 
adding 750 ml of 80% Ethanol to 250 ml Eosin Y stock solution. Add 5 ml glacial 
acetic acid and mix well. Store at room temperature. 
10. DPX mountant for histology (06522, Sigma) 
11. Cover slip Best No.1, 22 mm x 50 mm (12342118, Thermo Scientific) 
 
3. Methods  
3.1 Tamoxifen administration 
1. Gently warm the Tamoxifen solution on a heated stirrer until completely liquid.  
2. Intraperitoneal injection, subcutaneous injection and oral gavage have been 
reported as successful administration routes (6,23,25). The optimal route of 
administration depends on a range of factors that need to be considered for each 
specific experimental design; factors to consider are deposition and leakage of oil 
after subcutaneous injection; interaction of oil with Wt1-expressing, mesothelial 
tissues after intraperitoneal injection; and feasibility of oral gavage (25; BW, 
unpublished observations).   
3. Typically, the doses for Tamoxifen administration range between 1-2 mg 
Tamoxifen per 10 g body weight. Dosing regimens depend on the experimental 
design and range from once at a specific time point during embryonic development in 
case of embryonic lineage tracing, to 2-5 times within a week for postnatal or adult 
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lineage tracing (see Note 6). The pharmacological half-life of Tamoxifen after a 
single dose of Tamoxifen has been reported to be about 12 hours (26). 
 
3.2 Embryo and tissue harvesting  
Mouse embryos are staged from the time point when a vaginal plug was observed, 
which is designated as the stage E0.5. Embryos and neonate/adult mice are 
sacrificed, dissected and embryos/tissues washed in PBS before further processing. 
The respective national and local animal experimental guidelines need to be 
followed for the sacrifice of pregnant dams or newborn/adult animals. 
 
3.3 Immunofluorescence analysis of reporter distribution on frozen sections 
1. Embryos/tissues are fixed at room temperature in 4% freshly prepared 
paraformaldehyde (PFA) solution in PBS for 2–8 h (depending on the size) in 30-50 
ml universal containers. The tissue is washed in PBS and cryoprotected by incubating 
in 15% sucrose solution at 4 °C until it sinks to the bottom of the container. This is 
followed by incubation in 30% sucrose solution at 4 °C until the tissue has sunk.  
2. Embryos/tissues are placed in Peel-A-Ways or other embedding molds and as much 
of the sucrose solution is removed as possible using tissue paper before OCT is added 
to the mold to go at least 1 cm over the embryo/tissue. The embryos/tissues are snap 
frozen in liquid N2-cooled isopentane. Plastic tubes with isopentane are kept for a few 
minutes in liquid N2 and then the embryos are rapidly submerged in the isopentane. 
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Cooling of isopentane with dry ice is also possible. The frozen embryos are wrapped 
in foil and stored at -80°C.  
3. Cryosections of 7-10 μm thickness are obtained on a cryostat, collected on glass 
slides and stored at -20 °C until use. YFP expression is strong enough to be directly 
detected by confocal microscopy (Figures 3A, B).  
4. For immunofluorescence detection of reporter and marker proteins, cryosections 
are air-dried, rehydrated for 5 minutes in TPBS and blocked during 30 minutes for 
non-specific binding with SB or SBT for membrane-bound and intracellular 
antigens, respectively. When using biotinylated secondary antibodies, the 
endogenous biotin must be blocked at this step with the Avidin-Biotin blocking kit, 
according to the instructions on the supplier. In this case, the sections should be 
washed for 5 minutes in TPBS before adding the primary antibody.  
5. Single immunofluorescence is performed incubating the sections with the primary 
antibody overnight at 4° C. The antibody is dissolved in SB or SBT as indicated in 
the former point. Then, the sections are washed in TPBS (3x5 minutes) and 
incubated with the corresponding fluorochrome-conjugated secondary antibody 
dissolved in SB or SBT for 1 hour at room temperature in the dark. If nuclei are to 
be counterstained with DAPI, the working solution can be added to the solvent of 
the secondary antibody to a final concentration of 1 g/ml of DAPI. Alternatively, 
the sections can be stained with the working solution described in the section 2.3.9 
(see Notes 7, 8).  
6. For double immunofluorescence, two primary antibodies (for example a rabbit 
polyclonal and a mouse or rat monoclonal) are incubated in combination overnight 
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at 4°C, in SB or SBT as described in the former section. After a wash step with 
TPBS, the sections are incubated for 1 hour with the corresponding secondary 
antibodies conjugated to different fluorochromes (eg. phycoerythrin and Alexa-647) 
and DAPI (1 g/mL final concentration), diluted in SB or SBT, allowing for three-
color images (Figure 3A, B).  
7. When the primary antibodies are generated in different species (e.g. rat, mouse 
and rabbit), it is even possible to perform triple immunofluorescence. In this case, 
rat and rabbit primary antibodies, and the corresponding secondary antibodies are 
incubated first as described above. Then, the sections are incubated for 1 hour at 
room temperature with monovalent donkey anti-mouse IgG, Fab fragment (see Note 
9) diluted 1:100 in TPBS, followed by washing in TPBS (3x5 minutes) and 
incubation with the mouse primary antibody, washing and the corresponding anti-
mouse IgG secondary antibody conjugated to a compatible fluorochrome with those 
used previously. Counterstaining with DAPI allows for four-color images, but it is 
important to take in account that confocal images are captured only in three channels 
(red, green and blue), being any additional color combination of them.  
8. After final wash in TPBS (3x5 minutes), the sections are mounted with 
glycerol:PBS 1:1 or commercial mounting media and protected from the light.  
 
3.4 X-gal staining on frozen sections  
1. Embryos/tissues can be directly frozen in OCT without prior fixation, and stored 
at -80 °C until further use. Cryosections obtained from the unfixed tissue are fixed 
for 10 min in cold 4% PFA and washed three times in PBS.  
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2. The X-gal dilution buffer is set up, warmed to 37 °C and then 40 mg/ml X-gal 
stock solution added. The slides are incubated in X-gal working solution in a 
humidified chamber placed in an incubator at 37°C for 24 hours.  
3. The sections are washed in PBS for 2 x 5 minutes (mins), rinse with distilled 
water briefly and counterstain with neutral red for 3-5 mins. After washing in 
distilled water the sections can be dehydrated in alcohol and mounted with Eukitt 
mounting medium. 
See Note 10. 
 
3.5 X-Gal whole mount staining of embryos/tissues 
1. Large mouse embryos (over E13.5) or whole organs need to be sectioned with a 
scalpel (e.g. sagittally) to improve penetration of the staining solution. 
Embryos/tissues are fixed in 0.2% Glutaraldehyde/2% PFA fixative at 4 C for 10-
15 mins (small embryos), 15-30 mins (large embryos over E13.5) or 1-2 hours (adult 
tissues) in 20 ml universal containers.  
2. The embryos/tissues are washed 3 times for 30 mins in wash solution, followed 
by incubation in X-gal staining solution in the dark at room temperature (see Note 
11). The stained embryos/tissues are postfixed overnight in 4% PFA at 4 C, and 
after a few PBS washes, stored in 70% ethanol.  
 
3.6  Histological analysis of X-gal stained whole embryos/tissues 
1. Postfixed X-gal stained embryos/tissues are dehydrated through an ethanol series 
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(25%, 50%, 75%) into 100% ethanol (twice), with each step lasting 15-30 mins at 
room temperature. The ethanol is then replaced by isopropanol for two incubation 
steps of at least 15 mins each.  
2. The embryo/tissue is incubated in a pre-warmed, well-mixed 1:1 
Isopropanol:Paraffin solution in a histology incubator at 58-60 °C for 1 hour. The 
Isopropanol:Paraffin solution is subsequently replaced by fresh paraffin and after a 
short incubation for 1 hour in the incubator, the embryo/tissue is incubated in a fresh 
change of paraffin in the incubator overnight.  
3. The next day, the embryo/tissue is placed inside embedding molds or Peel-A-
Ways and covered by paraffin. This step is easiest when done using an embedding 
station. It is important to consider the desired orientation of the sections and 
achieving the correct orientation especially for small embryos can be tricky (see 
Note 12). The tissue block is allowed to solidify overnight before sectioning. For 
long-term storage, the blocks are stored at 4 °C. 
4. Using a microtome, sections of 5-10 μm are generated as ‘ribbons’, and collected 
on glass slides with the help of water (for example histology water bath at 45-50 °C) 
to facilitate even spreading of the sections. Sections are subsequently dried for 30 
mins at RT, followed by baking in an incubator at 45-50 °C overnight. Sections can 
be stored in slide boxes at room temperature or 4 °C until further use (see Note 13). 
5. For Eosin counter staining, sections are dewaxed by 2 incubation steps in Xylene 
(or Histoclear as alternative) in a glass rack in a staining dish on a stirrer, where the 
small stir bar is placed between glass rack and glass trough. Note that Xylene steps 
require work in a fume cupboard. 
20 
 
6. Pass the slides in the glass rack through a series of ethanol changes, starting with 
2 changes of 100% Ethanol, and incubation steps in 95%, 75% and 50% Ethanol for 
5 mins each. Slides are subsequently placed in PBS. It is important that sections 
must not be allowed to dry from this step onwards.  
7. Slides are incubated for 1 min in Eosin staining solution (see Note 14, 15). This is 
followed by a wash step in tap water for 1 min, and a dehydration series from 50% 
to 100% Ethanol for 2-5 mins each. Slides are incubated twice for 2 mins in Xylene 
(or Histoclear) before embedding with mounting medium using coverslips. A typical 
result of this procedure is shown in Figure 8.  
 
4. Notes  
1. Note that Tamoxifen is an anti-cancer drug used in cancer patients. Tamoxifen 
acts as an antagonist of the estrogen receptor through its active metabolite 4-
hydroxytamoxifen. It is therefore essential that health and safety aspects of 
workers exposed to Tamoxifen are being considered before work is started. 
2. Different concentrations of Tamoxifen solutions, using different types of oils 
(peanut, sunflower), are reported in the literature. 
3. Sucrose solutions will be prone to contamination with yeast or fungi. Discard 
container after 2 weeks. 
4. For long term storage, upon opening the bottle, aliquot 25% Glutaraldehyde 
grade II solution into 10 ml aliquots (15 ml universal containers), and store at -20 
°C. 
5. Nonidet P-40 is highly viscous, so exact measurement of the 1 ml Nonidet P-40 
may not be possible. 
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6. Tamoxifen can affect the delivery of litters in pregnant females. If lineage tracing 
is required to last from embryonic to postnatal stages, it is therefore 
recommended that the pups are recovered by Caesarian section and placed with a 
foster dam. Lineage tracing in newborn pups can be facilitated via Tamoxifen 
administration to the lactating dam. 
7. Cryosections are routinely stained with a panel of antibodies to identify the 
(developmental) fate of the Wt1-expressing cell lineage. Use of secondary 
antibodies conjugated to fluorochromes compatible with YFP, such as TRITC, 
phycoerythrin, Cy5, Alexa-647, or infrared-emitting fluorochromes allows for 
triple or quadruple staining. 
8. Negative controls should always be performed by incubating with non-immune 
species-matched isotype IgG instead of the primary antibodies. 
9. The monovalent antibody blocks potential binding sites on the rat IgG for the 
anti-mouse IgG secondary antibody. 
10. Alternatively, β-galactosidase expression can be detected by 
immunofluorescence (protocol 3.3) using the rabbit anti-β-galactosidase 
primary antibody (#559762) from Cappel/MPI (Figure 6). 
11. Depending on the level of β-galactosidase expression, staining may take 
between a few hours to overnight (Figure 7). 
12. Use fine forceps that are pre-warmed in the histology incubator or the 
embedding station, to orient the embryo in the paraffin, and place the mold onto 
the hot spot of the embedding station. This allows the paraffin to stay liquid for 
a bit longer. One of the problems can be the formation of a solid sheet at the 
surface, which prevents visualisation of the embryo. Removing the solidifying 
sheet at the surface repeatedly will provide an additional short time window in 
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which to orient the embryo. In general, it is important to work fast, and to know 
beforehand which way the embryo should be oriented. 
13. X-gal staining on sections can be detected by eye or under a microscope 
(depending on the strength of the signal), allowing the selection of relevant 
sections for Eosin counter staining. It is important to note that the tissue in the 
paraffin sections does not allow for a proper evaluation unless dewaxed, 
counter-stained (optional), appropriately dehydrated and permanently mounted 
with cover slips.  
14. The Eosin counter staining provides a pink staining to the tissue section. The 
Eosin staining solution is acidic and the staining reaction is based on its binding 
to basic cells and tissue structures, including the cytoplasm of cells.  
15. The optimal time for incubation in the Eosin staining solution depends on its 
strength and needs to be determined individually. 
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Figure Legends 
Figure 1. Direct expression of GFP as a reporter for Wt1, in the Wt1
tm1Nhsn
 mouse 
line, generated by replacing exon1 and part of the intronic region of the Wt1 gene by 
a GFP-cassette containing construct (Ref. 98). A. Wt1-GFP expression in glomeruli 
of an adult kidney bisected shortly after dissection and visualised with a fluorescence 
dissecting microscope. B. In this section of the kidney of an adult mouse, GFP was 
immunostained using the chicken polyclonal anti-GFP (Abcam, ab13970). Wt1 (GFP) 
expression is clearly localized in the glomerular podocytes. Endothelial cells are 
immunostained in red.  
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Figure 2. Schematic diagram delineating the constitutive Cre/loxP-based Wt1 lineage 
tracing system. The system consists of two genetic components: Transgenic mice 
generated by inserting a Cre recombinase expressing sequence under control of a Wt1 
promoter (Wt1
Cre
), and gene-targeted mice where a stop sequence flanked by lox sites 
is placed in front of a YPF cassette in the Rosa26 locus (Rosa26R-YFP reporter). 
Offspring of crosses between Wt1
Cre
 and Rosa26-YFP reporter mice, result in 
embryos which carry both genetic modifications, allowing permanent expression of 
YFP in Wt1-expressing cells and their lineage. Thus, YFP expression remains active 
even when Wt1 and Cre recombinase expression has been switched off in a particular 
cell. 
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Figure 3. Permanent lineage tracing with the mWt1/IRES/GFP-Cre;Rosa26R-YFP 
model. The lineage of the cells that have expressed Wt1, constitutively express YFP 
which can be directly observed by confocal microscopy. A. Immunostaining of 
anoctamin (red) in the intestine of an E16.5 embryo. The calcium-activated chloride 
channel anoctamin is expressed in progenitors of the visceral smooth muscle, and 
some of which express YFP and therefore are part of the Wt1 lineage. B. Double 
immunofluorescence of an artery in the lungs of an E18.5 embryo. Smooth muscle is 
shown in red and endothelium in blue. YFP+ cells can be seen forming part of the 
endothelium (arrows). C, D. Despite the presence of a GFP sequence in the plasmid 
construct used to generate this model, expression of GFP is too low to be detected 
(C), and does not interfere with the strong expression of YFP (D).  
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Figure 4. For temporal control of reporter expression (here: β-Galactosidase) in cells 
of the Wt1 lineage, the system consists of two genetic components similar to the 
model shown in Figure 2. However, to allow temporal control of Cre activity in Wt1-
expressing cells, the Cre recombinase is fused to a modified estrogen receptor (ERT2; 
Wt1
CreERT2
 mouse line). The Cre-ERT2 fusion protein can only enter the nucleus 
when binding of Tamoxifen to the ERT2 component of the fusion protein has led to a 
conformational change. In the absence of Tamoxifen, the Cre-ERT2 fusion protein is 
localised in the cytoplasm. In Tamoxifen-treated mice carrying both the Wt1
CreERT2
 
and the Rosa26R-LacZ reporter, the Cre recombinase will remove the loxP-flanked 
stop cassette after Tamoxifen administration leading to permanent reporter 
expression. However, cells expressing Wt1 in subsequent days will not be labelled 
through Cre recombination. This means that the lineage of Wt1 expressing cells can 
be followed from a specific, defined time point, for example during embryonic 
development.  
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* 
* 
Figure 5. Endogenous GFP fluorescence of live mesothelial cells grown out of 
omentum explants in culture, isolated from a Wt1
CreERT2
;Rosa26R-mTmG mouse 15 
weeks after Tamoxifen-induced recombination. * indicate artificially blacked out 
areas of fluorescence of the omentum explant. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Detection of the β-Galactosidase reporter by immunofluorescence and 
confocal microscopy. A. Expression in an E13.5 embryo of the Tg(WT1)HNdh Wt1 
reporter line. Putative Wt1 expressing cells can be seen in the mesothelium of the 
spleen primordium, located in the mesogastrium, and also in cells within the spleen. 
St, stomach. B. Immunolocalization of β-Galactosidase in the intestine of a E11.5 
Wt1
Cre
;Rosa26-LacZ embryo.  
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Figure 7. Detection of the β-Galactosidase reporter by X-gal staining of whole adult 
tissue. A. X-gal staining of bisected whole kidney of an adult Wt1
CreERT2
;Rosa26R-
LacZ mouse 5 months after Tamoxifen pulse. Only glomeruli show X-gal staining, 
indicating that they have expressed Wt1 at the time of Tamoxifen administration. B. 
Histological section of the X-gal-stained kidney shown in A, counterstained with 
Eosin. X-gal staining is confined to the glomeruli. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Detection of the β-Galactosidase reporter by X-gal staining of whole 
embryos which were stained, paraffin-embedded and sectioned. A. X-gal expression 
in an E10.5 embryo of the Tg(WT1)HNdh Wt1 reporter line, showing staining in 
intermediate mesoderm and mesenterium. B. X-gal expression staining cells from the 
Wt1 lineage in the digestive tract of an E11.5 mWt1/IRES/GFP-Cre;Rosa26LacZ 
embryo.  
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